Mayo Clinic Laboratory and Pathology Research Roundup: July 18

By brentwestra • July 18, 2016

Share this:

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including a featured article of the week, abstracts, and complete list of published studies and reviews.

Featured Abstract

The Histone H3.3K36M Mutation Reprograms the Epigenome of Chondroblastomas

More than 90% of chondroblastomas contain a heterozygous mutation replacing lysine-36 with methionine-36 (K36M) in the histone H3 variant H3.3. Mayo Clinic researchers conducted a study to show that H3K36 methylation is reduced globally in human chondroblastomas and in chondrocytes harboring the same genetic mutation, due to inhibition of at least two H3K36 methyltransferases, MMSET and SETD2, by the H3.3K36M mutant proteins. Genes with altered expression as well as H3K36 di- and trimethylation in H3.3K36M cells are enriched in cancer pathways. In addition, H3.3K36M chondrocytes exhibit several hallmarks of cancer cells, including increased ability to form colonies, resistance to apoptosis, and defects in differentiation. Thus, H3.3K36M proteins reprogram the H3K36 methylation landscape and contribute to tumorigenesis, in part through altering the expression of cancer-associated genes. The study was published in Science. 

Published to PubMed This Week

• Standardized Mixed-Meal Tolerance and Arginine Stimulation Tests Provide Reproducible and Complementary Measures of β-cell Function: Results From the Foundation for the National Institutes of Health Biomarkers Consortium Investigative Series
  Diabetes Care
• The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging
  Journal of the American Society of Nephrology
• Should Apolipoprotein B Replace LDL Cholesterol as Therapeutic Targets Are Lowered?
  Current Opinion in Lipidology
• Silent Tyrosinemia Type I Without Elevated Tyrosine or Succinylacetone Associated With Liver Cirrhosis and Hepatocellular Carcinoma
  Human Mutation
  
• Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea
  Journal of Clinical Gastroenterology
• Double Red Blood Cell Collection: Comparison of Three Apheresis Systems
  Transfusion
• Pseudolipoblastic Perineurioma: An Unusual Morphological Variant of Perineurioma that May Simulate Liposarcoma
  Human Pathology
  
• Pre- and Post-Operative Predictors of Infection Related Complications in Patients Undergoing Percutaneous Nephrolithotomy
  Journal of Endourology
• c-Met Expression and MET Amplification in Malignant Pleural Mesothelioma
  Annals of Diagnostic Pathology
• Triathlete Risk of Pelvic Floor Disorders, Pelvic Girdle Pain, and Female Athlete Triad
  Female Pelvic Medicine & Reconstructive Surgery

brentwestra

Brent Westra is a Marketing Segment Manager at Mayo Clinic Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.